Topline
Health regulators in the U.K. on Tuesday approved Novo Nordisk’s weight loss injection semaglutide—the active ingredient in Ozempic and Wegovy—for lowering the risk of cardiovascular events in adults with obesity, after research indicated the high-demand drug was beneficial in…
[ad_2]
Source link
